Collegium Pharmaceutical Inc (COLL)

[floblu14]

ELYXYB home page -

https://www.elyxyb.com/

[floblu14]

As of tomorrow - March 22 - A DONE DEAL -

As a result of its acceptance of the Shares tendered in the Offer, Purchaser acquired sufficient Shares to effect the Merger without the affirmative vote of BDSI’s stockholders. Accordingly, Collegium and Purchaser expect to consummate the Merger on March 22, 2022 pursuant to Section 251(h) of
the DGCL.

https://ir.collegiumpharma.com/static-files/cec34a91-1356-4843-8704-625d10abc5f0

[floblu14]

28 new career positions listed now after restructuring loss of approximately 50 positions.

Getting ready for the acquisition of BDSI at end of this month.

Among them is this post -

Senior Manager of Regulatory Affairs

POSITION OVERVIEW

The Senior Manager, Regulatory Affairs will play a leadership role in providing Regulatory support for Collegium’s marketed products and development programs. Manage regulatory input into project tams and provide regulatory strategies to ensure appropriate implementation of key business initiatives. This role will be the single point of contact between the Company and Health Authorities such as the Food and Drug Administration (FDA), Health Canada, and the European Medicines Agency (EMA).

Responsibilities

Lead international product registration and licensing Review and interpret regulatory rules as they relate to company products and procedures, clinical studies, testing, or records keeping and ensure that they are communicated through company policies and procedures

Influence and contribute to the short and long term Regulatory planning of new product opportunities

Serve as the primary contact between Collegium and Regulatory Authorities such as the FDA, Health Canada, and the EMA

Own Investigational New Drug (IND) and New Drug Application (NDA) submissions to the FDA to support development programs and Collegium marketed products

https://careers-collegiumpharma.icims.com/jobs/1513/senior-manager-of-regulatory-affairs/job

[floblu14]

Talk about insider info/trades prior to quarterly earnings report -

https://ir.collegiumpharma.com/static-files/19eea55c-e0d9-4c0f-ae57-3142c43d32af

[floblu14]

Collegium Pharmaceutical price target raised to $42 from $36 at Piper Sandler 06:03 COLL, BDSI Piper Sandler analyst David Amsellem raised the firm's price target on Collegium Pharmaceutical (COLL) to $42 from $36 and keeps an Overweight rating on the shares following the BioDelivery Sciences (BDSI) acquisition announcement. The analyst believes that visibility into EBITDA in excess of $300M by 2023 is relatively high. Show Related Items >>

Read more at:
https://thefly.com/n.php?id=3463057

[floblu14]

Dr. Jessica Ailani and Dr. Peter McAllister share their views on ELYXYB™ (celecoxib) oral solution, the first and only FDA-approved treatment of its kind for MIGRAINES.

Watch video -
https://vimeo.com/639176222?embedded=true&source=vimeo_logo&owner=138775481

[floblu14]

Analysts' Upgrades -

A. Cantor upgrades Collegium on revenue diversification from deal 16:28 COLL, BDSI Cantor Fitzgerald analyst Brandon Folkes upgraded Collegium Pharmaceutical (COLL) to Overweight from Neutral with a price target of $26, up from $18, following the company's acquisition of BioDelivery Sciences (BDSI). The upgrade is driven by the diversification in revenue in which the deal brings, as well as a footprint in the adjacency neurology category, Folkes tells investors in a research note. The analyst believes Collegium's newly diversified revenue streams and therapeutic focus are both "multiple enhancing." Folkes adds that while his overall concerns with the branded Xtampza and OxyContin market decline has not subsided, the start of 2022 offers "some hope that the decline could stabilize this year."

Read more at:
https://thefly.com/n.php?id=3458996

B. Collegium Pharmaceutical price target raised to $29 from $26 at H.C. Wainwright

C. Collegium Pharmaceutical price target raised to $34 from $28 at Needham 07:16 COLL, BDSI

[floblu14]

Collegium to Acquire BioDelivery Sciences Broadening Pain Portfolio
February 14, 2022 at 6:30 AM EST

Expected to be Immediately and Highly Accretive Driven by Identified Annual Synergies of at Least $75 Million -

- Will Diversify Revenue Growth and Accelerate Cash Flow Generation -

- Addition of BELBUCA® Provides a Second Growth Driver and ELYXYB™ Establishes Foothold in Neurology -

- Conference Call Scheduled for Today at 8:30 a.m. ET -

STOUGHTON, Mass. and RALEIGH, N.C., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) and BioDelivery Sciences International, Inc. (NASDAQ: BDSI) today announced a definitive agreement pursuant to which Collegium will acquire BDSI for $5.60 per share in cash.

BDSI has a portfolio of pain and neurology products that address serious and debilitating conditions. BDSI’s commercial growth driver, BELBUCA, is a meaningfully differentiated schedule III opioid product and is highly complementary to Collegium’s portfolio of pain products. Additional products in the BDSI portfolio include Symproic®, a contributor, and ELYXYB, a neurology product in its early launch phase.

“We are excited to announce this acquisition, which represents a major step forward in our mission to build a leading, diversified specialty pharmaceutical company committed to improving the lives of people suffering from serious medical conditions,” said Joe Ciaffoni, President and Chief Executive Officer of Collegium. “The BDSI portfolio expands and enhances Collegium’s differentiated pain offerings and establishes a foothold in neurology, a strategic market adjacency. Importantly, we expect this acquisition will be immediately and highly accretive by expanding our revenue scale and generating significant synergies.”

“We are pleased to announce the transaction with Collegium, which we view as a testament to the attractiveness of our portfolio and long-term value of our brands,” said Jeff Bailey, Chief Executive Officer of BDSI. “Our team has worked diligently to grow our differentiated products. We believe that this transaction will deliver benefits to patients and prescribers and create significant value for our shareholders.”

Transaction Rationale

Strategically aligned with Collegium’s mission to build a leading, diversified specialty pharmaceutical company committed to improving the lives of people suffering from serious medical conditions

Diversifies and expands Collegium’s revenues by adding BELBUCA as a second and highly complementary growth driver to Collegium’s highly differentiated pain portfolio, in addition to a contributor with Symproic, and a new product launch opportunity with ELYXYB

Further strengthens Collegium’s financial position through increased revenue scale, immediate and significant earnings accretion, and accelerated cash flow generation, driven by identified annual run rate synergies of at least $75 million expected to be achieved within twelve months post-closing

ELYXYB provides entry into the neurology market, a strategic market adjacency previously identified by Collegium
Additional Transaction Details

Under the terms of the definitive agreement, Collegium will promptly commence a tender offer to acquire all the outstanding shares of BDSI at the price of $5.60 per share

The offer price of $5.60 represents a 54% premium to BDSI closing share price of $3.64 as of Friday, February 11, 2022, and implies a fully diluted equity value of approximately $604 million using the treasury stock method
The all-cash consideration will be funded by a combination of Collegium existing cash on hand and a $650 million secured financing from funds managed by Pharmakon Advisors, LP (“Pharmakon”), with a four-year term, which will bear an interest rate of Libor+750bps and will be amortized over four years

As part of the transaction, Collegium will repay the existing Collegium term loan from Pharmakon and the existing BDSI term loan from Pharmakon

Post-closing, we expect Collegium net leverage to be below 3.0x based on estimated fiscal year 2021 pro forma combined EBITDA including run rate synergies

Collegium expects to achieve annual run rate synergies of at least $75 million, based off of BDSI estimated 2021 operating expenses, within twelve months post-closing

Collegium expects this transaction to be highly accretive to earnings in 2022 and 2023
Timing to Close

The transaction, which has been unanimously approved by the boards of directors of both companies, is expected to close late in the first quarter 2022, subject to customary closing conditions, including receipt of required regulatory approvals and the tender of a majority of outstanding shares of BDSI’s common stock. Following the successful closing of the tender offer, Collegium will acquire any shares of BDSI that are not tendered in the tender offer through a second-step merger at the same consideration as paid in the tender offer.

https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-acquire-biodelivery-sciences-broadening-pain-portfolio

[floblu14]

From COLL career posts -
We will continue to work hard to position Collegium to usher in a next generation of non-opioid pain solutions in the US market.

FDA NEWS RELEASE

FDA Takes Steps Aimed at Fostering Development of Non-Addictive Alternatives to Opioids for Acute Pain Management

https://www.fda.gov/news-events/press-announcements/fda-takes-steps-aimed-fostering-development-non-addictive-alternatives-opioids-acute-pain-management

___________________________________________

Amended statement of ownership -

Vanguard owns 6.62% of COLL

https://ih.advfn.com/stock-market/NASDAQ/collegium-pharmaceutical-COLL/stock-news/87235991/amended-statement-of-ownership-sc-13g-a

[floblu14]

January 28, 2022
A Form SC 13G/A has been filed with the United States Securities and Exchange Commission.
View this filing ?
https://ir.collegiumpharma.com/static-files/a1aa0b3b-4a52-4c4d-92c6-c056887cc664

BlackRock, Inc. now owns 5550301 shares or 16.3% of Collegium

What Can a Schedule 13D Tell an Investor?

A Schedule 13D is a document that must be filed with the Securities and Exchange Commission (SEC) within 10 days of the purchase of more than 5% of the shares of a public company by anyone investor or entity. It is sometimes referred to as a beneficial ownership report.1?

This document, which is publicly available, provides useful information about majority ownership in the company. It reveals the name, ownership amount, and stated intentions of any investor who has purchased a substantial share of a company.2? (The buyer might not intend an outright takeover. It might, for example, be a purchase by an activist investor seeking more management input.)

KEY TAKEOVERS
The Schedule 13D is a required SEC filing for entities acquiring more than 5% of the stock of a public company.

It is seen as a signal of an imminent corporate takeover.

Significant information in the 13D includes the source of the funds used for the purchase.1?

Read more:
https://www.investopedia.com/ask/answers/09/schedule-13d.asp

[floblu14]

What does this tell you?

Principal Financial Group Inc. Acquires 25,684 Shares of Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical logoPrincipal Financial Group Inc. grew its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 2.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,057,611 shares of the specialty pharmaceutical company’s stock after acquiring an additional 25,684 shares during the period. Principal Financial Group Inc. owned about 3.06% of Collegium Pharmaceutical worth $20,878,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of COLL. Peregrine Capital Management LLC bought a new stake in shares of Collegium Pharmaceutical during the 3rd quarter valued at $13,464,000. Dimensional Fund Advisors LP grew its position in shares of Collegium Pharmaceutical by 33.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 775,908 shares of the specialty pharmaceutical company’s stock valued at $18,344,000 after acquiring an additional 193,468 shares during the period. Massachusetts Financial Services Co. MA grew its position in shares of Collegium Pharmaceutical by 29.4% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 832,554 shares of the specialty pharmaceutical company’s stock valued at $19,682,000 after acquiring an additional 189,232 shares during the period. Federated Hermes Inc. boosted its holdings in Collegium Pharmaceutical by 76,168.4% in the 2nd quarter. Federated Hermes Inc. now owns 171,604 shares of the specialty pharmaceutical company’s stock worth $4,057,000 after buying an additional 171,379 shares during the period. Finally, LSV Asset Management bought a new position in Collegium Pharmaceutical in the 3rd quarter worth $2,899,000.

https://etfdailynews.com/news/principal-financial-group-inc-acquires-25684-shares-of-collegium-pharmaceutical-inc-nasdaqcoll/

[floblu14]

Best Value Pharmaceutical Stocks - 12 Jan.

These are the pharmaceutical stocks with the lowest 12-month trailing price-to-earnings (P/E) ratio. Because profits can be returned to shareholders in the form of dividends and buybacks, a low P/E ratio shows you’re paying less for each dollar of profit generated.

https://www.investopedia.com/investing/pharmaceutical-stocks/?utm_campaign=quote-yahoo&utm_source=yahoo&utm_medium=referral

[floblu14]

COLL recommendation - January 3

Sonic Automotive And 5 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

https://via.news/markets/sonic-automotive-5-other-stocks-high-sales-growth-an-above-3-return-equity-3/

[floblu14]

“We are pleased to be in a position to resolve these cases and move forward. We remain committed to our mission of being the leader in responsible pain management,” said Shirley Kuhlmann, Executive Vice President, General Counsel of Collegium.

Collegium Announces Settlement Framework to Resolve Pending Opioid-Related Litigation

https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-announces-settlement-framework-resolve-pending-opioid

Now - UP!

[floblu14]

Three items:

A. Current restructuring is eliminating approximately 50 positions. However, 9 new career listings are now posted -

https://careers-collegiumpharma.icims.com/jobs/search?mobile=false&width=1170&height=500&bga=true&needsRedirect=false&jan1offset=-300&jun1offset=-240

B. Jeffries recommends COLL -

https://www.thestreet.com/investing/jefferies-small-caps-callaway-january

C. Dreyer Scott, EVP & Chief Commercial Officer, sells 5,693 shares at $18.33. Probably to buy holiday gifts for Joe Ciaffoni.

https://ir.collegiumpharma.com/static-files/7482db0d-8b8c-4e7c-9bf8-37969521eab9

[floblu14]

Besides the moon & the stars - who reads these posts? LOL

Analysts Expect Collegium Pharmaceutical, Inc. (NASDAQ:COLL) to Announce $1.04 Earnings Per Share 12/9/2021

Collegium Pharmaceutical Wall Street analysts expect that Collegium Pharmaceutical, Inc. (NASDAQ:COLL) will report $1.04 earnings per share (EPS) for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Collegium Pharmaceutical's earnings, with the lowest EPS estimate coming in at $0.96 and the highest estimate coming in at $1.09. Collegium Pharmaceutical posted earnings per share of $0.20 in the same quarter last year, which indicates a positive year over year growth rate of 420%. The company is expected to issue its next quarterly earnings results on Thursday, February 24th.

https://www.marketbeat.com/instant-alerts/nasdaq-coll-consensus-analyst-rating-2021-12/

[floblu14]

10 Growth Stocks Under $20 in Billionaire Ken Fisher’s Portfolio

Mon, December 6, 2021, 1:42 PM

10. Collegium Pharmaceutical, Inc. (NASDAQ:COLL)
Number of Hedge Fund Holders: 13

Price as of December 5, 2021: $17.61 per share

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) is a pharmaceutical company that focuses on developing medicines for pain management. Latest data shows that Fisher Asset Management owned 20,349 shares of the company at the end of the third quarter of 2021 worth $402,000.

HC Wainwright analyst Oren Livnat has a Buy rating on Collegium Pharmaceutical, Inc. (NASDAQ:COLL) stock with a price target of $26. In a recent investor note, the analyst appreciated the potential of pipeline drugs of the firm.

Among the hedge funds being tracked by Insider Monkey, New York-based firm Rubric Capital Management is a leading shareholder in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) with 2.6 million shares worth more than $51 million.

At the end of the third quarter of 2021, 13 hedge funds in the database of Insider Monkey held stakes worth $144 million in Collegium Pharmaceutical, Inc. (NASDAQ:COLL), down from 16 in the preceding quarter worth $209 million.

Just like Apple Inc. (NASDAQ:AAPL), Microsoft Corporation (NASDAQ:MSFT), Amazon.com, Inc. (NASDAQ:AMZN), and Alphabet Inc. (NASDAQ:GOOG), Collegium Pharmaceutical, Inc. (NASDAQ:COLL) is one of the stocks on the radar of growth investors.

https://finance.yahoo.com/news/10-growth-stocks-under-20-184250597.html

[floblu14]

Needham Thinks Collegium Pharmaceutical’s Stock is Going to Recover
November 26 2021 - 11:15AM

In a report released today, Serge Belanger from Needham maintained a Buy rating on Collegium Pharmaceutical (COLL – Research Report), with a price target of $28.00. The company's shares closed last Friday at $17.83, close to its 52-week low of $17.67. According to TipRanks.com, Belanger is a 3-star analyst with an average return of 1.8% and a 38.5% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Amphastar Pharmaceuticals, and KalVista Pharmaceuticals. Currently, the analyst consensus on Collegium Pharmaceutical is a Strong Buy with an average price target of $27.00.

https://ih.advfn.com/stock-market/NASDAQ/collegium-pharmaceutical-COLL/stock-news/86665851/needham-thinks-collegium-pharmaceutical-s-stock-i

[floblu14]

New Corporate slide show presentation at Jefferies - Nov. 18:

Select Pages 14, 15 & 22

https://ir.collegiumpharma.com/static-files/a38f74ec-ad9f-48d8-b0a2-37766a071619

[floblu14]

FWIW -

These 40 Mass. companies made the new Deloitte Fast 500 list https://www.bizjournals.com › boston › news › 2021/11/17

The list, released Wednesday, ranks the fastest-growing technology, media, telecommunications and life sciences companies based in North America.

Collegium Pharmaceutical Inc., No. 138

Realistically, even considering the buyback & the restructuring, they need to fire their PR department. This stock has stagnated for years.

Sell the company for $85 PPS!!

[floblu14]

Collegium Pharmaceutical price target lowered to $26 from $28 at H.C. Wainwright

H.C. Wainwright analyst Oren Livnat lowered the firm's price target on Collegium Pharmaceutical to $26 from $28 and keeps a Buy rating on the shares. The analyst sees Xtampza 20022 return to growth likely, with potential 2023 accelerations if contracts improved. Livnat added that COVID-related mix shift worsened in Q3, and that "all eyes" are now on the company's 2022 guidance and execution.

[floblu14]

IMHO - I wouldn't be surprised if TAKEDA bought out COLL.

Rationale:

COLL - is way too cheap! At 7 times earnings plus a $100M buyback - the stock has been going NO-WHERE. If this was a biotech - the stock would be $100+ PPS due to earnings alone.

Most importantly - Colleen Tupper - Prior to joining Collegium [in May 2021], Colleen most recently served as Chief Financial Officer, U.S. Business Unit as well as a member of the U.S. Business Unit Executive Leadership Team and the Global Finance Leadership Team at Takeda.

Prior to that role, Colleen held several roles of increasing responsibility at Shire Pharmaceuticals (acquired by Takeda in 2019) including Vice President, U.S. Commercial Finance, Vice President, Finance Integration Lead, and Vice President, Head of Finance Global Neuroscience and Ophthalmics.

https://www.collegiumpharma.com/people/colleen-tupper/
______________________________________

On April 19, 2018 Takeda made an official bid of about $66.22 (U.S.) per share, which had a value of about $60 billion (U.S.). ... Under the final bid, Shire agreed to be acquired for about $62.2 billion (U.S.), or $66.22 per share, made up of $30.33 per share in cash and 0.839 shares of Takeda stock. Jan 8, 2019

[floblu14]

$COLL - Collegium Pharmaceuticals DCF - 20 October 2021

[floblu14]

General Counsel sells small amount of shares (734) -

https://ir.collegiumpharma.com/static-files/70d4a3b0-5d35-4b2e-a045-866dd489bd97

[floblu14]

COLL vs. ZTS: Which Stock Should Value Investors Buy Now?
Zacks Equity Research
Mon, September 20, 2021, 11:40 AM

ZTS
+0.14%

COLL
-1.01%

Investors interested in Medical - Drugs stocks are likely familiar with Collegium Pharmaceutical (COLL) and Zoetis (ZTS). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.

The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits.

Collegium Pharmaceutical and Zoetis are sporting Zacks Ranks of #1 (Strong Buy) and #3 (Hold), respectively, right now. The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that COLL has an improving earnings outlook. However, value investors will care about much more than just this.

Value investors also try to analyze a wide range of traditional figures and metrics to help determine whether a company is undervalued at its current share price levels.

Our Value category grades stocks based on a number of key metrics, including the tried-and-true P/E ratio, the P/S ratio, earnings yield, and cash flow per share, as well as a variety of other fundamentals that value investors frequently use.

COLL currently has a forward P/E ratio of 5.31, while ZTS has a forward P/E of 43.84. We also note that COLL has a PEG ratio of 0.27. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. ZTS currently has a PEG ratio of 3.17.

Another notable valuation metric for COLL is its P/B ratio of 2.76. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. For comparison, ZTS has a P/B of 21.62.

Based on these metrics and many more, COLL holds a Value grade of A, while ZTS has a Value grade of C.

COLL stands above ZTS thanks to its solid earnings outlook, and based on these valuation figures, we also feel that COLL is the superior value option right now.

https://finance.yahoo.com/news/coll-vs-zts-stock-value-154003011.html

[floblu14]

Top Pharmaceutical Stocks for Q4 2021

Best Value Pharmaceutical Stocks
These are the pharmaceutical stocks with the lowest 12-month trailing price-to-earnings (P/E) ratio. Because profits can be returned to shareholders in the form of dividends and buybacks, a low P/E ratio shows you’re paying less for each dollar of profit generated.

Collegium Pharmaceutical Inc.: Collegium Pharmaceutical is a pharmaceutical company specializing in pain management. It develops medications to treat acute and chronic pain. The company announced in mid-August that its board of directors authorized the repurchase of up to $100 million of the company's common stock. The timing and amount of share repurchases will be determined by management.

https://finance.yahoo.com/m/844e8960-46d3-33bd-9ae1-3dea2d091a69/top-pharmaceutical-stocks-for.html

[stocksrising]

Any thoughts on EPS?

[stocksrising]

Thought the Jeffries presentation went well, but stock action doesn’t it seems?

[stocksrising]

Nice Invite to join S&P SC600! More institutions the better??

[floblu14]

Positive signs - SEC FILINGS

Most shares granted to COLL officers were acquired & HELD, NOT sold:

https://ir.collegiumpharma.com/sec-filings

[floblu14]

Collegium Pharmaceutical (NASDAQ:COLL), is a small-cap drug maker focused on the treatment of chronic pain. The company’s products are designed to address the problems of abuse and addiction in the opioid market. With nearly 20 million Americans suffering from chronic pain issues, this Massachusetts-based company will not lack for a patient base.

The product line at Collegium includes two pain-relief drugs: Xtampza, a 10-to-12-hour, controlled release version of oxycodone, and Nucynta, an opioid of similar effect to oxycodone but with fewer reported side effects. Xtampza, as a controlled-release formulation is less potent than morphine, and potentially less prone to abuse.

Collegium showed $79.2 million in revenue for 3Q20, the last quarter reported, with a net earnings of 32 cents per share. Both of these figures were up sequentially – earnings by 39%. Year-over-year, the gains were more impressive: EPS was up from an 18-cent loss in the year-ago quarter, while revenue was up 8.6% in the same period.

Covering Collegium from H.C. Wainwright, analyst Oren Livnat sees the company taking a solid position in its niche.

“[We’re] confident in strong early-2021 volume acceleration. Then, we’re hopeful that Collegium can drive moderated but continued volume growth through the year as it works to gain market share in the 22M commercial lives where Xtampza now has parity positioning vs. OxyContin… we see gross margin upside bolstered by improved Nucynta profitability… We continue to see Collegium stock as extremely cheap at just 5.3x our 2021 EBITDA,” Livnat wrote.

It’s not surprising, then, why Livnat gives COLL an Outperform (i.e. Buy) rating. His $33 price target supports his bullish stance, and suggests a 50% one-year upside

https://www.investing.com/analysis/3-top-biotech-stocks-that-score-a-perfect-10-200555929

[floblu14]

Collegium Pharmaceutical price target raised to $33 from $29 at H.C. Wainwright

[floblu14]

Collegium Provides 2021 Financial Guidance
Collegium Pharmaceutical, Inc.
Wed, January 6, 2021, 4:01 PM EST

– Xtampza® ER Revenues Expected in the Range of $155.0 million to $165.0 million –

– Nucynta® Franchise Revenues Expected in the Range of $175.0 million to $185.0 million –

– Adjusted EBITDA Expected in the Range of $160.0 million to $170.0 million –

STOUGHTON, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced its 2021 full-year financial guidance.

“Collegium achieved a financially transformative year in 2020, driven by Xtampza ER growth and the acquisition of the Nucynta franchise. We delivered on our broad operational objectives and prioritized the health and safety of our people, customers and the communities that we serve,” said Joe Ciaffoni, President and Chief Executive Officer of Collegium. “As we head into 2021, we remain steadfast in our commitment to being the leader in responsible pain management, maximizing the potential of our differentiated pain portfolio and creating value for our shareholders.”

“Our 2021 revenue outlook is supported by Xtampza ER growth, stable profit contribution from the Nucynta franchise and a commitment to leverage our cost structure,” said Paul Brannelly, Executive Vice President and Chief Financial Officer of Collegium. “This year, we expect to generate significant cash flow from operations and will deploy our balance sheet in a disciplined manner that invests in the long-term growth of our company.”

Financial Guidance for 2021

Xtampza® ER revenues are expected in the range of $155.0 million to $165.0 million

Nucynta® franchise revenues are expected in the range of $175.0 million to $185.0 million

Adjusted EBITDA (excluding stock-based compensation) is expected in the range of $160.0 million to $170.0 million

Total operating expenses are expected in the range of $125.0 million to $135.0 million

https://finance.yahoo.com/news/collegium-provides-2021-financial-guidance-210100747.html

[floblu14]

Investing $5,000 in These 2 Biotechs Could Make You Rich
These two companies aren't reinventing the wheel, but they still have the potential for tremendous growth.

Dated 25 October 2020

Collegium Pharmaceuticals (NASDAQ:COLL) and Athenex (NASDAQ:ATNX) may not be the most popular stocks on the market in terms of media coverage, but both might just make you rich with a well-timed investment. Unlike many of their compatriots in the world of small market cap biotechs, these two companies have regularly recurring revenues. While neither has consistently profitable operations at present, evidence suggests that they can achieve it within the next few years, making each a great candidate for investors' portfolios

What's more, these two stocks have similar paths toward profitability: Increasing the sales volume of their existing products on the market while finalizing their late-stage pipeline projects and moving them toward commercialization. There's going to be a lot going on with these companies over the near term, and growth investors should pay close attention if they want to have a shot at reaping the benefits of their successes. Let's dive in and explore Collegium and Athenex's prospects.


Collegium has gotten its first taste of profits

Collegium, a pain medicine company, derives its revenue from opioid analgesics that have been formulated for extended release. By changing the formulation of these highly effective medicines to include delayed release and other anti-abuse features, Collegium hopes to steal market share from generic opioid pain medicine manufacturers as well as branded opioid analgesics, both of which carry a high risk of addiction. Given the state of the opioid abuse epidemic in the U.S., Collegium's approach could provide clinicians the pain-relief tools their patients need, but without as much risk of future abuse.

Collegium has three products that are approved for sale, including its Xtampza extended release oxycodone tablets for pain relief. Since its regulatory approval in 2016, Xtampza has proven popular. The drug holds 23.5% of the extended-release market for oxycodone as of Q2 2020, ended June 30, up from 21.8% market share in Q1. The company expects the drug's market share to increase as a result of new development activity, which should lead to two new therapy formulations relatively soon.

In the meantime, Collegium posted a profit for the first time in the recent quarter, thanks to Xtampza sales of $33.6 million -- an increase of 29% from the same quarter last year. But its profitability is still tenuous, with a margin less than 1%. Nonetheless, Xtampza's growth appears to be accelerating rather than slowing down, which puts Collegium on a trajectory that could make its shareholders rich as its products become the go-to for pain relief, especially in areas where opioid abuse is rife.

Read more:
https://www.fool.com/investing/2020/10/25/investing-5000-in-these-2-biotechs-could-make-you/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article

[floblu14]

Disclosure - as a former, LUCKY shareholder of MOMENTA PHARMACEUTICALS, I am now an official Collegium. Also, big into REVANCE THERAPEUTICS - RVNC.

Here's some great COLL news -

29 December:
Needham names Collegium Pharma Top Pick for 2021, adds to Conviction List 07:35 COLL, RVNC Needham analyst Serge Belanger named Collegium Pharmaceutical (COLL) as his 2021 best idea and added the company to Needham Conviction List in place of Revance Therapeutics (RVNC), which was removed. The analyst is also keeping his Buy rating and $34 price target on Collegium. Belanger states that the growth prospects of the company's Xtampza within the "complex" opioid market remains its "key value driver" with significant sales growth expected next year, but the investment story has grown to include its "stabilized" Nucynta franchise. The analyst believes that Nucynta could contribute to Collegium's top-line growth and a "leverageable" cost structure that will further improve the company's profitability and cash generation.

Read more at:
https://thefly.com/n.php?id=3218629

Regards,

FLO

[stocksrising]

Incredible things are c’ing our way!

[luvwetscent]

Coll has 95% institutional ownership and recent upgrades....Elite..?????..zero

[NASDAQ2020]

Sell now and buy back at 15.

Collegium (COLL) has an ER ADF opioid – Xtampza (physical-chemical), an extended-release product for which the company received FDA approval in April 2016 has all three ADF labels. According to the information available, while on the Express Scripts formulary, they are having less than stellar sales and have a small pipeline.

[luvwetscent]

Collegium will be a huge winner going forward

[luvwetscent]

Well here i am Nas...dump Elite..buy Coll

[Gator44]

Their Nucynta drug didn't help with my neuropathy pain. Gave up using it after month try. Maybe that's why they're selling it.

[Apophis]

Addicts figured this one out already.

The active ingredient can be removed by warming the tablets to 170 F and then squeeze the beeswax out with a press.

The FDA was sleeping when this got approved?

[zerowinner]

What’s with the slide in this stock?

[Apophis]

EGLT is also working on this stuff, 30 cent stock right now

[NASDAQ2020]

Collegium gets mention in new abuse deterrent article:

https://seekingalpha.com/article/4206069-abuse-deterrent-opioids-business-answer-opioid-abuse-crisis

[Apophis]

This company has ripped off a 20 year old process used with many drugs

[Apophis]

Drug components micronized and imbedded in bees wax? Collegenium infringed on a patent that was used 20 years ago with potassium chloride supplements , the US patent office should have never granted them a patent.

https://www.researchgate.net/publication/263443938_Sustained_release_of_KCl_from_BeeswaxCarnauba_wax_microparticles


https://patents.google.com/patent/US4822619A/en

I kind of knew this process sounded familiar , they are in lots of trouble.

[Apophis]

Depomed farms out Nucynta sales, will lay off 40% of company
BY MarketWatch
— 5:03 PM ET 12/04/2017
DepoMed Inc.
) announced Monday afternoon that it will allow Collegium Pharmaceutical Inc. ( COLL ) to handle sales of its most lucrative product, the Nucynta line of painkillers, and slash its workforce. DepoMed
) said that it would take royalties as Collegium markets and sells Nucynta, and eliminate its painkiller salesforce and any brand advertising for the product. The company plans to lay off 40% of its workforce, about 70 employees, and move its headquarters out of Newark, California, to a state on the East Coast or in the Midwest. "Taking these steps, in terms of headcount reductions and office relocation, will provide additional financial and strategic benefits," DepoMed
) Chief Executive Arthur Higgins,who took the reins of the company earlier this year after an activist-investor battle (http:// www.marketwatch.com/story/depomed-dives-as-activist-investor-fight-leads-to-new-ceo-board-members-2017-03-28), said in a prepared statement. DepoMed
) will receive a minimum royalty of $135 million a year while cutting $70 million in annual expenses, the company said. Through nine months of this year, DepoMed
) has reported $183.3 million in Nucynta sales, more than half of its $286.3 million in total revenue. DepoMed
) and Collegium shares were both halted for a little more than a half-hour in late trading ahead of the announcement; after trading resumed, DepoMed ( DEPO ) shares, which were down more than 60% on the year, gained nearly 5% and Collegium shares added about 0.4%.

[Apophis]

I cant believe they have sub contracted the manufacturing. They could have done this themselves along with marketing and saved over 200 million. They gave away the lions share of profit.

[fenixrizin]

Excellent. Please short the stock and then post a message in 1 year from now.